Tarafenacin, also known as SVT-40776, is a novel M3 muscarinic receptor antagonist under development for the treatment of overactive bladder. SVT-40776 shows highly selective for M(3) over M(2) receptors (Ki = 0.19 nmol.L(-1) for M(3) receptor affinity). SVT-40776 is a potent inhibitor of M(3) receptor-related detrusor contractile activity. The absence of effects on isolated atria preparations represents an interesting characteristic and suggests that SVT-40776 may lack unwanted cardiac effects; a feature especially relevant in a compound intended to treat mainly elderly patients.
MedKoo Cat#: 319859
Name: Tarafenacin
CAS#: 385367-47-5
Chemical Formula: C21H20F4N2O2
Exact Mass: 408.1461
Molecular Weight: 408.40
Elemental Analysis: C, 61.76; H, 4.94; F, 18.61; N, 6.86; O, 7.84
The following data is based on the product molecular weight 408.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
